Skip to main content
Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
11.62
+0.72 (6.61%)
Nov 13, 2026, 4:00 PM EST - Market closed

Fennec Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
66.3744.6447.5421.251.54-
Revenue Growth
71.09%-6.09%123.69%1284.50%802.94%-
Cost of Revenue
3.893.763.181.260.09-
Gross Profit
62.4740.8844.3519.991.45-
Selling, General & Admin
58.4246.9141.4832.7120.5112.24
Research & Development
0.340.250.310.063.534.98
Operating Expenses
58.7647.1641.7932.7624.0417.22
Operating Income
3.72-6.282.57-12.77-22.59-17.22
Interest Expense
-0.35-2.14-4.16-3.68-1.13-0.14
Interest & Investment Income
1.170.791.680.440.20.05
Currency Exchange Gain (Loss)
-0.020.03-0.080.01-0.01-0.01
EBT Excluding Unusual Items
4.53-7.610.01-16.01-23.53-17.32
Gain (Loss) on Sale of Investments
--0-0.08-0.04-0.18-0.03
Other Unusual Items
-2.02-2.02----
Pretax Income
2.51-9.64-0.07-16.05-23.71-17.35
Income Tax Expense
0.480.110.37---
Net Income
2.03-9.74-0.44-16.05-23.71-17.35
Net Income to Common
2.03-9.74-0.44-16.05-23.71-17.35
Net Income Growth
------
Shares Outstanding (Basic)
342927272626
Shares Outstanding (Diluted)
352927272626
Shares Change
28.15%4.70%2.71%1.14%1.03%9.71%
EPS (Basic)
0.06-0.34-0.02-0.60-0.90-0.67
EPS (Diluted)
0.06-0.34-0.02-0.60-0.90-0.67
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
94.13%91.57%93.30%94.08%94.40%-
Operating Margin
5.60%-14.07%5.40%-60.09%-1471.60%-
Profit Margin
3.05%-21.82%-0.92%-75.50%-1544.89%-
EBITDA
3.82-6.183.6---
EBITDA Margin
5.76%-13.84%7.57%---
D&A For EBITDA
0.10.11.03---
EBIT
3.72-6.282.57-12.77-22.59-17.22
EBIT Margin
5.60%-14.07%5.40%-60.09%--
Revenue as Reported
66.3744.6447.5421.25--
SEC Filings: 10-K · 10-Q